IP Library Granted Patent US 9,932,402
Granted Patent B2
US 9,932,402 · App. 13/661,386 · Granted Apr 3, 2018

Humanized antibodies to iNKT

Inventors: Alemseged Truneh (Sudbury, MA); Francis Joseph Carr (Aberdeen, GB); Timothy David Jones (Cambridgeshire, GB); James P. Gregson (Cheshire, GB)
Assignee: NKT Therapeutics Inc.
C07K16/2809A61K2039/505A61K2039/543C07K2317/24C07K2317/41C07K2317/56C07K2317/71C07K2317/72C07K2317/73C07K2317/732C07K2317/734C07K2317/75C07K2317/76C07K2317/90C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,932,402
App. No.
13/661,386
Granted
Apr 3, 2018
Kind
B2
Abstract

Methods of treatment to suppress an immune response are provided. The method comprises administering to a subject in need of treatment a naked blocking antibody that binds selectively iNKT cells in an amount effective to suppress the subject's iNKT cell function. Compositions comprising, an isolated, humanized antibody that binds selectively iNKT cells are also provided.

Claims (7)

1. A method of treatment to suppress an immune response, comprising administering to a subject in need of treatment a naked blocking antibody that binds selectively to iNKT cells in an amount that is effective to suppress the subject's iNKT cell function, wherein the subject has an airway hyper-reactivity condition or sickle cell anemia, and wherein the antibody comprises a heavy chain with a sequence that is SEQ ID No. 27 and a light chain with a sequence that is SEQ ID No. 29.

2. The method of claim 1 , wherein the subject has an airway hyper-reactivity condition and the airway hyper-reactivity condition is asthma.

3. The method of claim 2 , wherein the asthma is allergic asthma.

4. The method of claim 1 , wherein the subject has an airway hyper-reactivity condition and the airway hyper-reactivity condition is COPD.

5. The method of claim 1 , wherein the subject has an airway hyper-reactivity condition and the treatment suppresses in the subject one or more symptoms of the condition.

6. The method of claim 1 , wherein the subject is human.

7. The method of claim 1 , wherein the subject has sickle cell anemia.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2013
From: TRUNEH, ALEMSEGED
To: NKT THERAPEUTICS INC.
Reel/Frame 030055/0615 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2013
From: CARR, FRANCIS JOSEPH; JONES, TIMOTHY DAVID; GREGSON, JAMES P.
To: ANTITOPE LIMITED
Reel/Frame 030055/0644 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2013
From: ANTITOPE LIMITED
To: NKT THERAPEUTICS INC.
Reel/Frame 030055/0649 →
Continuity (2)
Provisional Application 61552337 · Oct 27, 2011
Related Publication 20130136735A1 · May 30, 2013